Flotetuzumab

MacroGenics Enters Research Collaboration with Janssen to Develop Novel DART® Molecule

Retrieved on: 
Friday, December 18, 2020

MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced today a research collaboration and global license agreement to develop a preclinical bispecific molecule with Janssen Biotech, Inc.

Key Points: 
  • MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced today a research collaboration and global license agreement to develop a preclinical bispecific molecule with Janssen Biotech, Inc.
  • The research collaboration will incorporate MacroGenics' proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology.
  • Under the terms of the agreement, Janssen will pay MacroGenics an upfront payment of $20 million and will be responsible for funding all expenses.
  • MacroGenics will also be eligible to receive up to $312 million in potential milestone payments and tiered royalties on worldwide product sales.

MacroGenics Announces Flotetuzumab Publication in Blood Advances

Retrieved on: 
Thursday, October 15, 2020

This represents the third publication of flotetuzumab data in 2020.

Key Points: 
  • This represents the third publication of flotetuzumab data in 2020.
  • The same gene signature was shown to be associated with an increased probability of this subset of patients to respond to flotetuzumab.
  • These individuals represent approximately 40-50% of all AML patients, said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics.
  • 1 Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia , Blood, 2020; and Immune Landscapes Predict Chemotherapy Resistance and Immunotherapy Response in Acute Myeloid Leukemia , Science Translational Medicine, 2020.

MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual Meeting

Retrieved on: 
Monday, December 9, 2019

Furthermore, the same gene signature was associated with patients more likely to respond to flotetuzumab, supporting the mechanism being exploited by this molecule.

Key Points: 
  • Furthermore, the same gene signature was associated with patients more likely to respond to flotetuzumab, supporting the mechanism being exploited by this molecule.
  • Flotetuzumab, an Investigational CD123 x CD3 Bispecific DART Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
    Abstract #460: Vadakekolathu, et al.
  • ET to review the flotetuzumab data presented at the ASH Annual Meeting and discuss ongoing clinical development plans.
  • Approximately 40-50% of newly diagnosed patients fail to achieve a complete remission with intensive induction therapy (primary induction failure) or experience disease recurrence after a short remission duration (

MacroGenics Announces Flotetuzumab Presentations at the ASH Annual Meeting 2019

Retrieved on: 
Wednesday, November 6, 2019

ET to review the flotetuzumab data presented at the ASH annual meeting and discuss ongoing clinical development plans.

Key Points: 
  • ET to review the flotetuzumab data presented at the ASH annual meeting and discuss ongoing clinical development plans.
  • To participate in the MacroGenics ASH 2019 Conference Call, please dial (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and provide the Conference ID: 3625435.
  • MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer.
  • Anna Krassowska, Ph.D., Vice President, Investor Relations & Corporate Communications Jim Karrels, Senior Vice President, CFO MacroGenics, Inc. 1-301-251-5172, [email protected]

Global Bispecific Antibody Market to 2025: Drug Sales & Clinical Pipeline Insights with an $8 Billion Market Opportunity

Retrieved on: 
Friday, January 18, 2019

The "Global Bispecific Antibody Market, Drug Sales & Clinical Pipeline Insight 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Bispecific Antibody Market, Drug Sales & Clinical Pipeline Insight 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Currently, there are 2 bispecific antibodies (HEMLIBRA and Blincyto) commercially available in the market with combined sales of less than US$ 1 Billion in 2018.
  • The market for bispecific antibodies is quiet bright as they are the new emerging trends in the market.
  • Global Bispecific Antibody Market, Drug Sales & Clinical Pipeline Insight 2025 Report Highlights:
    Global Bispecific Antibody Market Overview: Drug & Market Sales
    Global Bispecific Antibody Market Opportunity: US$ 8 Billion by 2025
    US & Japan Market Share Opportunity: >40% by 2025

Global Bispecific Antibody Market: Drug Sales & Clinical Pipeline Insight, 2025 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 16, 2019

The "Global Bispecific Antibody Market, Drug Sales & Clinical Pipeline Insight 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Bispecific Antibody Market, Drug Sales & Clinical Pipeline Insight 2025" report has been added to ResearchAndMarkets.com's offering.
  • Global Bispecific Antibody Market Overview: Drug & Market Sales
    Global Bispecific Antibody Market Opportunity: US$ 8 Billion by 2025
    US & Japan Market Share Opportunity: >40% by 2025
    As per report findings, the market opportunity of bispecific antibodies is estimated to surpass US$ 8 Billion by 2025 driven by application of existing commercially available bispecific antibodies to other multiple indications and increasing regulatory approvals from developing and developed markets.
  • Currently, there are 2 bispecific antibodies (HEMLIBRA and Blincyto) commercially available in the market with combined sales of less than US$ 1 Billion in 2018.
  • No Development Reported & Discontinued Global Bispecific Antibodies Clinical Pipeline by Company, Indication & Phase